Overview

Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
The planned study has two purposes: 1. It is to provide evidence that the administration of a cholinesterase inhibitor will result in an increase of IGF-I (primary variable) and in an increase of the secretion growth hormone (secondary variable) that can be maintained throughout the treatment-period of one year. 2. The study also tests the hypothesis that maintenance of increased blood levels of growth hormone and IGF-I can stop or delay the age-related changes of body composition (secondary variables) .
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Ludwig Boltzmann Gesellschaft
Treatments:
Cholinesterase Inhibitors
Donepezil
Hormones
Criteria
Inclusion Criteria:

- Aged between 70 and 80 years

Exclusion Criteria:

- Cardiac arrhythmias (sick sinus syndrome, AV block, sino-atrial block),

- Treatment with beta-blockers, NSAIDs or cholinergic agonists,

- Known hypersensitivity to donepezil hydrochloride, piperidine derivatives or to any
excipients used in the formulation,

- Gastric and duodenal ulcer,

- Severe renal and hepatic impairment,

- Urinary congestion (prostatic hypertrophy),

- Obstructive pulmonary disease (bronchial asthma);